hC Bioscience Announces Lead Program in Hemophilia and Reports Positive Preclinical Data on Novel Protein Editing Approach Using Anticodon Engineered tRNA
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc., a biotech company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases and cancer, today announced it has expanded its executive and research & development teams with the additions of Yosef Landesman, Ph.D., as chief scientific officer and Gautam Goel, Ph.D., as chief data science officer.